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Edited by Lukas HuberAbstract Previous studies found that lysophosphatidic acid
(LPA) upregulated Fas ligand (FasL) presentation on the ovar-
ian cancer cell surface and lead to apoptosis of activated lympho-
cytes. In this report, we investigated the role of selective
induction of cyclooxygenase-2 (Cox-2) in FasL cell surface pre-
sentation stimulated by LPA. Ovarian cancer cells pretreated
with general aspirin derivative acetylsalicylic acid and speciﬁc
Cox-2 inhibitor (NS-398) before stimulation with LPA, FasL
cell surface presentation was signiﬁcantly blocked, so was the
apoptosis of activated lymphocytes mediated by increasing FasL
on the ovarian cancer cell surface. Using the speciﬁc inhibitors
PD98059, AG1478 or dominant-negative epidermal-growth-
factor receptor (EGFR-DN) plasmid, we found that the activa-
tion of ERK1/2 played a role in Cox-2 induction, and the
transactivation of EGFR worked as an upstream signaling path-
way in ERK1/2 phosphorylation. This study ﬁrst revealed the
selective induction of Cox-2 by LPA led to FasL presentation
on ovarian cancer cell surface and provide cancer cell immune
privilege, and might provide important information of Cox-2 in
cancer progression and Cox-2 inhibitors’ application in cancer
chemoprevention.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The lack of early eﬀective diagnostic approaches with high
mortality rate makes ovarian cancer a strong candidate for che-
moprevention [1]. The recent reports revealed that both cycloox-
ygenase-1 (Cox-1) and cyclooxygenase-2 (Cox-2)were expressed
in ovarian epithelial cancers and might contribute to ovarian
cancer development or metastasis [2]. But Cox-1 expressionAbbreviations: Cox-2, cyclooxygenase-2; ASA, acetylsalicylic acid; NS-
398 (NS), Cox-2 inhibitor; Cox-1, cyclooxygenase-1; FasL, Fas ligand;
LPA, lysophosphatidic acid; sPLA2- IIA, type II secretory PLA2; G-
PCR, G-protein-coupled receptor; ERK, extracellular signal regulated
kinase; EGFR, epidermal-growth-factor receptor; PDGFR, platelet-
derived growth factor receptor; FACS, ﬂow cytometry; AA, arachi-
donic acid
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doi:10.1016/j.febslet.2005.12.033was constitutive in epithelia ovarian cancer and found also in
normal ovarian epithelium, while Cox-2 expression was induc-
ible and frequently found at the advancing margin of tumor
invasion or in newmetastatas [2–4]. The increasedCox-2 expres-
sion is associated with chemotherapy resistance and outcome in
these patients [5,6]. Reports indicated that overexpression of
Cox-2 may lead to cell phenotypic changes, which may alter
the angiogenic andmetastatic potential of cancer cells [7,8]. Epi-
demiological observations suggest that inhibition of Cox-2 by
non-steroidal anti-inﬂammatory drugs (NSAIDs) may decrease
the development of ovarian cancer and serve as a strategy of che-
moprevention for ovarian cancers [9,10]. However, the role of
Cox-2 in Fas ligand (FasL) expression and immune regulation
has not been explored in ovarian cancer cells.
The cellular messenger molecule lysophosphatidic acid
(LPA, 1-acyl-sn-glycerol 3-phosphate) is a naturally occurring
glycerophospholipid that elicits growth factor-like cellular re-
sponses. LPA is highly elevated in ascites from ovarian cancer
patients [11,12]. LPA evokes a diverse range of physiological
and pathological responses, including mitogenesis, inhibited
apoptosis, actin cytoskeleton reorganization and increased
ovarian cancer cell motility [11,13–15]. Type II secretory
PLA2 (sPLA2-IIA), involved in lipid metabolism, functions
as a cell-associated enzyme and regulated by extracellular cyto-
kines or growth factors, is critical to signal transduction of
pro-inﬂammatory lipid mediators [16,17]. Co-localization
and functional coupling of Cox-2 and sPLA2-IIA have been
reported [18,19]. Our previous works revealed that LPA
strongly upregulated FasL presentation on ovarian cancer cell
surface and induced apoptosis of activated T lymphocytes [17].
Though the results indicated that extracellular signal regulated
kinase (ERK) kinase cascade was required for FasL upregula-
tion, the inhibitor of sPLA2-IIA, however, only partially inhib-
ited ERK phosphorylation and activation, suggesting that
additional pathways may participate in ERK upstream activa-
tion in response to LPA. Epidermal-growth-factor receptor
(EGFR) transactivation and tyrosine phosphorylation linked
to the G protein-coupled receptors (GPCRs) activation have
been clearly elucidated [20,21]. While others argue that ERK
activation may also through the platelet-derived growth factor
receptor (PDGFR) transactivation [22,23]. Besides, the corre-
lations of signaling pathways and the abnormal expressions
of Cox-2 and EGFR are still questionable [5,24,25].
We therefore, ﬁrst investigated the selective Cox-2 induction
by LPA and its role in FasL cell surface presentation stimu-
lated by LPA in ovarian cancer cells. We found the speciﬁcblished by Elsevier B.V. All rights reserved.
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sentation induced by LPA. These results may support the pos-
sible clinical application of Cox-2 inhibitors in ovarian cancer
chemoprevention. Secondly, we explored the upstream signal-
ing pathways in ERK activation by EGFR transactivation
upon LPA stimulation.Fig. 1. Eﬀect of LPA on Cox-2 protein and mRNA expression. (A)
Ovarian cancer cells were serum starved for 2 h, incubated with LPA
for 16 h. Cells were lysed and subjected to Western blot with anti-Cox-
2 or anti-Cox-1 antibodys. Data shown are one representative of three
independent and reproducible experiments. (B) Cells treated as above
were harvested and intracellular Cox-2 was immunodetected by FACS.
Isotype-matched antibody was used as control. With increasing
concentrations, LPA induced intracellular Cox-2 expression in
OVCAR3 cells. Data shown are one representative of three indepen-
dent and reproducible experiments. (C) RNA was extracted from cells
treated as above for 2 h or with 80 lM LPA for diﬀerent time courses,
Cox-2 mRNA were ampliﬁed by RT-PCR. Data shown are one of two
independent and reproducible experiments. (D) Cox-2 activity assay:
cells were serum starved and stimulated with diﬀerent concentrations
of in the presence of AA for 24 h, the spent medium was harvested and
levels of PGE2 were measured. Data shown were one of the
representatives of three independent and reproducible experiments.2. Materials and methods
2.1. Cell culture and reagents
Acetylsalicylic acid (ASA) was from Sigma Chemical Co., St. Louis,
MO; Cox-2 inhibitor (NS-398, NS), PD98059, AG1478, and AG1296
were from Calbiochem (California). All cell lines, culture conditions
and other materials were previously described [15].
2.2. FasL and Cox-2 immunodetection
FasL staining and analytic procedures were previously described
[17]. To increase the levels of membrane-bound FasL, cells were pre-
treated with 10 lMmatalloproteinase (MMP) inhibitor GM6001 (Cal-
biochem, CA). For intracellular Cox-2 staining, cells were
permeabilized and ﬁxed ﬁrst, then incubated with anti-huCox-2-FITC
mAb (BD Pharmingen). Isotype murine IgG1-FITC serves as control.
Stained cells were analyzed by ﬂow cytometry (FACS).
2.3. Western blot analysis
As previously described [15], Simply, cell lysate was separated on
12% SDS–PAGE gels and transferred to membranes, then stained with
the primary anti-Cox-2 , anti-Cox-1 or anti-FasL (Santa Cruz Biotech-
nology), anti-ERK1/2 or anti-phosphoryted-ERK1/2 (p-ERK1/2, Cell
Signaling Technology). The membranes were washed and then stained
with the secondary anti-rabbit immunoglobulin-horseradish peroxi-
dase (Santa Cruz Biotechnology). Protein bands were visualized by
ECL Western blotting detection system (Amershan).
2.4. RT-PCR
Total RNA was isolated using Sigma GenElute Mammalian Tatal
RNA kit. Reverse transcription was performed using Promega Access-
Quick RT-PCR System according to the manufacturer’s instructions.
Cox-2 mRNA were ampliﬁed by the primers for human Cox-2: 5 0-
TGGGAAGCCTTCTCTAACCTCTCCT-3 0 (forward), 5 0-CTTTGA-
CTGTGGGAGGATACATCTC-3 0 (reverse), with product length 388
bp. b-Actin was ampliﬁed using speciﬁc primers 5 0-AGCGGGAAAT-
CGTGCGTG-3 0 (forward) and 5 0-CAGGGTACATGGTGGTGCC-
3 0 (reverse) as control, yielding a 309 bp fragment. The PCR products
were analyzed on a Tris–EDTA (TAE) 1.5% agarose gel with ethidium
bromide.
2.5. Assay of Cox-2 activity
Cells were serum starved for 2 h and incubated with diﬀerent con-
centrations of LPA for 12 h in the presence or absence of arachidonic
acid (AA), the spent medium was harvested and prostaglandin E2
(PGE2) was measured utilizing negative ion chemical ionization–mass
spectrometry [26].
2.6. Co-culture of ovarian cancer cells with CD4+ T cells and apoptosis
detection
Ovarian cancer cells were pretreated with diﬀerent reagents. CD4+
cells were puriﬁed and activated, then added to adhesive ovarian can-
cer cells mono-layer [17]. Following co-culture for 24 h, non-adhesive
T cells were collected and stained with Annexin V-FITC and PI (BD
Pharmingen) and then analyzed by FACS.
2.7. Plasmid construction and transfection
The cDNA of EGFR-CD533 without the cytoplasm C-terminal 533
amino acids was previously described [27,28]. PCR product of the full
length of EGFR-CD533 was cloned into pcDNA3.1/NT-TOPO using
GFP Fusion TOPO TA Expression Kits (Invitrogen, Carlsbad, CA)
according to the instruction manual. Clones acquired were digested
and shown to be the right size inserted, and the correct coding anddirection was conﬁrmed by sequencing. The constructed pcDNA3.1/
NT-EGFR-CD533-GFP-TOPO was referred as EGFR-DN plasmid
thereafter. Ovarian cancer cells growing in 10 cm dish were transfected
with 5 lg EGFR-DN plasmid or 5 lg control vector pcDNA3.1/NT-
GFP (Invitrogen, Carlsbad, CA) using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA). Transfection eﬃciencies (>80%) were detected
by ﬂuorescence microscopy and FACS after 48 h.
2.8. Statistics
Statistical analysis was performed on GraphPad Instat. P < 0.05 was
accepted for signiﬁcance.3. Results
3.1. Selective induction of Cox-2 by LPA
To date, Cox-2 protein induction by LPA and/or sPLA2-IIA
has been controversial [8,19,29]. We tested if LPA may aﬀect
Cox-2 protein and mRNA expression in ovarian cancer cells.
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duced by LPA dose-dependently, meanwhile the constitutive
expression of Cox-1 was not aﬀected by LPA (Fig. 1A). Intra-
cellular FACS analysis further conﬁrmed the upregulation of
Cox-2 protein by LPA (Fig. 1B). RT-PCR analysis suggested
the increase of Cox-2 mRNA transcription by LPA, in both
dose-dependent and time-course increasing manner (Fig. 1C).
In the presence or absence of AA, cells were stimulated with
diﬀerent doses of LPA and the levels of PGE2 were detected.
Results conﬁrmed the increasing Cox-2 activity with increasing
doses of LPA treatment (Fig. 1D).
3.2. ASA and NS-398 inhibit FasL upregulation on the ovarian
cancer cell surface induced by LPA
Previous studies found LPA regulated FasL cell surface
expression and secretion [17]. To investigate if Cox-2 activity
may participate in FasL cell surface expression induced by
LPA, we pretreated OVCAR3 cells with ASA and Cox-2 spe-
ciﬁc inhibitor NS-398 before LPA treatment. We found that
both ASA and NS-398 dose-dependently blocked FasL cell
surface presentation induced by LPA (Fig. 2). The same exper-
iments were repeated with Dov13 cells for 3 times and similar
results were observed (data not shown). Cells treated as above
were lysed, however, Western blot did not show signiﬁcant
FasL protein level changes, suggesting the regulations of FasLFig. 2. Eﬀect of ASA and NS-398 on FasL cell surface expression
induced by LPA. OVCAR3 cells were serum starved for 2 h, pretreated
with ASA or NS-398 at the indicated concentrations for 1 h, then
incubated with 80 lM LPA for 16 h. Cells were harvested and FasL
was immunodetected by FACS. Isotype-matched antibody was used as
control. (A) With increasing concentrations, LPA upregulated FasL
presentation on OVCAR3 cell surface. (B) Cells were pretreated with
ASA then with 80 lM LPA as above. Compared to LPA alone, ASA
at 5 mM signiﬁcantly blocked FasL expression induced by LPA
(P < 0.05). (C) Cells were pretreated with NS-398 then with 80 lM
LPA as above. Compared to LPA alone, eﬀect of NS-398 at 50,
100 lM became signiﬁcant (P < 0.05, P < 0.001). Data shown are
mean values ± S.E.M. of three independent and reproducible experi-
ments. The same experiments were performed on Dov13 cells and
similar results were observed (data not shown). (D) Western blot of cell
lysate treated as above, there was no signiﬁcant FasL protein level
changes after ASA/LPA or NS-398/LPA treatment.by ASA/LPA or NS-398/LPA were most at post-translational
level (Fig. 2D).
3.3. ASA and NS-398 inhibit FasL mediated apoptosis of
activated lymphocytes by ovarian cancer cells
When activated puriﬁed human peripheral CD4+ lympho-
cytes were co-cultured with ovarian cancer cells, we found that
ovarian cancer cells induced the apoptosis of CD4+ lympho-
cytes [17]. Treatment Dov13 cells with LPA enhanced CD4+
lymphocytes undergoing apoptosis (Fig. 3A). However, pre-
treatment Dov13 cells with ASA or NS-398 before LPA treat-
ment signiﬁcantly blocked the enhancement (Fig. 3B). The
experiments were performed using OVCAR3 cells and the sim-
ilar results were observed (Fig. 3B). When anti-FasL neutraliz-
ing antibody was added the apoptosis of CD4+ lymphocytes
decreased, conﬁrming the apoptosis indeed was induced
through FasL and Fas interactions (Fig. 3B).
3.4. LPA regulates Cox-2 induction and FasL cell surface
expression through EGFR activation and ERK1/2
phosphorylation
By binding to pertussis-toxin-sensitive GPCRs, LPA rapidly
induced Cox-2 protein expression [29]. Though the activation
of ERK1/2 has often been reported to be the common down-
stream signaling pathway [30–32], multiple ligand-independentFig. 3. ASA and NS-398 inhibit FasL-expressing ovarian cancer cell
mediated apoptosis of activated lymphocytes. Ovarian cancer cells
were pretreated with ASA or NS-398, then with 80 lM LPA for 16 h.
After washing, IL-2 activated CD4+ lymphocytes were placed onto
these cells. After co-culture for 14 h, non-adherent CD4+ lymphocytes
were harvested, stained with Annexin V-FITC/PI, and analyzed by
FACS. (A) FACS analysis. (B) Annexin V-FITC staining cells were
calculated as apoptotic cells. Compared to LPA treated cells alone,
pretreatment cells with ASA (5 mM) or NS-398 (100 lM) signiﬁcantly
blocked apoptosis of CD4+ cells (\ P < 0.05,  P < 0.01 and § P < 0.05)
in both Dov13 and OVCAR3 cells. Data shown are mean val-
ues ± S.E.M. of three independent and reproducible experiments.
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including the EGFR and PDGFR, might work in several cel-
lular systems [20,22,23]. To investigate the complicated regu-
lating pathways involved in Cox-2 induction and FasL cell
surface presentation, we pretreated ovarian cancer cells with
speciﬁc kinase or receptor kinase inhibitors PD98059 (for
ERK1/2), AG1478 (for EGFR), AG1296 (for PDGFR) before
LPA stimulation. FACS revealed that both PD98059 and
AG1478 time consequentially inhibited intracellular Cox-2
expression and FasL cell surface presentation induced by
LPA (Fig. 4A, B). AG1296 had no eﬀect on either Cox-2 or
FasL expression (Fig. 4C). Western blot reaﬃrmed that the
Cox-2 protein expression was regulated by PD98059 and
AG1478 during LPA stimulation (Fig. 4D).
To further clarify FasL and Cox-2 expression signaling path-
ways regulated by LPA, EGFR-DN plasmid was constructedFig. 4. Signaling pathways involved in LPA induced Cox-2 induction and
pretreated with PD98059, AG1478 or AG1296 for 1 h, then incubated with
analysis of cell surface FasL and intracellular Cox-2. Artiﬁcial gates were set a
calculated. \P < 0.01 LPA treatment compared with control; P < 0.01 P
treatment alone; §P > 0.05 AG1496 pretreatment before LPA compared with
cells and the identical results were observed (data not shown). (D) Cells trea
protein expression. Figure shown is a typical experiment of three with identand transient transfection was performed in OVCAR3 cells
(Fig. 5A). In normal culture or control vector cells, LPA stim-
ulation signiﬁcantly induced ERK1/2 phosphorylation and
Cox-2 expression (Fig. 5B, lane 2 and lane 4). In cells pre-
treated with Ag1478 or EGFR-DN cells, ERK1/2 phosphory-
lation status or Cox-2 expression were close to basal levels,
conﬁrming that the ERK1/2 kinase activation was induced
through EGFR transactivation (Fig. 5B). After LPA treat-
ment, a slight but not signiﬁcant increase of FasL protein
expression was observed, conﬁrming the regulation of FasL
by LPA through induction of Cox-2 was most at post-transla-
tional. The basal level FasL protein level was relatively lower
in EGFR-DN cells (lane 5 and lane 6), but there was no signif-
icant increase of FasL protein after LPA treatment either.
However, FasL cell surface translocation induced in control
cells was signiﬁcantly blocked in EGFR-DN cells (Fig. 5C).FasL cell surface presentation. (A, B and C) OVCAR3 cells were
80 lM LPA for 16 h in the presence of the diﬀerent inhibitors. FACS
ccording to the isotype control and relative Cox-2 expressing cells were
D98059 or AG1478 pretreatment before LPA compared with LPA
LPA treatment alone. The same experiments were performed on Dov13
ted as above were lysed and Western blots were performed for Cox-2
ical results.
Fig. 5. Induction of Cox-2 by LPA was inhibited in EGFR-DN cells.
(A) Transfection eﬃciency of EGFR-DN plasmid compared with the
control vector. (B) OVCAR3 cells were transiently transfected with
EGFR-DN plasmid or control vector for 48 h, or pretreated with
AG1478 for 1 h before LPA treatment. Using cell lysate Western blots
were performed for FasL, Cox-2, pERK1/2 and total ERK1/2. (C)
OVCAR3 cells transfected as above and treated with LPA for 16 h,
FasL cell surface presentation were detected by FACS.
Fig. 6. Signaling pathways of FasL expression aﬀected by LPA. By
activation of sPLA2-IIA and transactivation of EGFR, LPA induced
signiﬁcant ERK1/2 phosphorylation and activation, which in turn lead
to Cox-2 mRNA and protein induction and FasL cell surface
translocation. MMPs may cleave FasL at the cell surface.
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Though the induction of Cox-2 has been reported to contrib-
ute to cancer growth and metastasis [8,33,34], our research ﬁrst
found that it might also provide ovarian cancer cell immune
privilege by upregulation of FasL. Numerous studies have
shown that FasL expression in vivo plays a role in cancer cell
counter attacking immune cells and tumor development
[35–37], since in tumor microenvironment, deaths of activated
immune T cells are FasL-dependent and might be directly reg-
ulated by FasL expression level [38,39]. Furthermore, the very
recent ﬁnding in animal model conﬁrmed that reduced FasL
expression by tumor cells led to increased lymphocyte inﬁltra-
tion [37]. When Cox-2 inhibitors signiﬁcantly blocked FasL
cell surface presentation and ovarian cancer cell induced
apoptosis of activated lymphocytes, immune balance and anti-
tumor response in tumor microenvironment might be restored.
Our study therefore provides support for Cox-2 inhibitors’
clinical applications in ovarian cancer chemoprevention [9,10].
In our experimental system, CD4+ helper T cells instead of
FasL expressing CD8+ cytolytic cells were used as target cell
during coculture to secure the FasL surface expressing ovarian
cancer cells as the one-way apoptosis inducing factor. In tumor
microenvironment, Fas expressing cancer cells may also face
FasL expressing CD8+ cytolytic T cells or NK cells, the fate
of individual cell may depend on the signiﬁcance of pro- or
anti-apoptosis signals. LPA quickly downregulates Fas on
the ovarian cancer cell surface ﬁrst [40], so the later FasL
upregulation would have little disadvantage on its own fate.
To the surrounding activated lymphocytes dramatic apoptosis
may happen since these cells usually upregulated Fas upon
activation [41]. A biomathematical prediction model shall ap-
ply into the tumor microenvironment and may guide clinical
combinational therapies. The combination of Cox-2 inhibitors
and MMP inhibitors have been providing additive therapeutic
beneﬁts in cancers [42–45]. Since LPA provides ovarian cancer
cell immune privilege while promote its invasiveness, we would
like to suggest to target the signaling initiator, LPA, whichmight be of primary importance in ovarian cancers prevention
and treatment [14,17].
Our study demonstrated that Cox-2 induction coupled to
ERK signaling activation played a role in LPA regulated FasL
cell surface presentation. This extends previous understanding
regarding LPA promote FasL cell surface translocation and
function through sPLA2-IIA via ERK activation [17,46].
LPA elicits multiple and complex biochemical signaling cas-
cades. The ligand-independent transactivation of protein tyro-
sine kinase receptors has been shown in several cellular systems
and seems to be a general possibility of signaling networks in
cancer cells [20,22,23,28]. Moreover, our study revealed the
ERK phosphorylation via EGFR transactivation played a sig-
niﬁcant role in LPA-mediated Cox-2 induction and FasL cell
surface presentation. The inhibition of fos gene expression
and DNA synthesis may explain the decrease of Cox-2 protein
and mRNA by inhibition of EGFR function through either
the speciﬁc inhibitor AG1478 or EGFR-DN [20,28]. Since
LPA also increased FasL microvesicle exocytosis, we cannot
exclude that LPA might regulate FasL protein expression,
somehow slightly, at translational level [17,46,47]. Together
with our previous investigations, detailed upstream signaling
pathways involved in FasL ovarian cancer cell surface presen-
tation regulated by LPA were explored and summarized
(Fig. 6).5. Conclusion
We found the selective induction of Cox-2 plays a role in
FasL cell surface presentation stimulated by LPA. Cox-2
inhibitors signiﬁcantly blocked FasL cell surface presentation
and ovarian cancer cell mediated apoptosis of activated lym-
phocytes. This research provides support for Cox-2 inhibitors’
clinical application in ovarian cancer chemoprevention. By
binding to GPCR on the ovarian cancer cell surface, LPA
transactivates EGFR followed by ERK1/2 activation to induce
Cox-2 mRNA and protein expression. These consequent
448 S. Kang et al. / FEBS Letters 580 (2006) 443–449events substantially aﬀect FasL protein cell surface presenta-
tion, providing ovarian cancer cells proinﬂammatory pheno-
type and immune privilege.
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